Therapeutic Handling of Infections Caused by Difficult-to-Treat Resistance (DTR) Gram-Negative Bacterial Pathogens: Is It Feasible?

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 18 November 2024 | Viewed by 59

Special Issue Editor


E-Mail Website
Guest Editor
1st Department of Internal Medicine-Infectious Diseases, Hygeia General Hospital, 4 Erythrou Stavrou & Kifisias, Marousi, 15123 Athens, Greece
Interests: newer antibiotics; antimicrobial stewardship; mechanisms of resistance

Special Issue Information

Dear Colleagues,

The rise of the 21st century coincided with the emergence of multi-drug-resistant Gram-negative bacteria, including extensively drug-resistant (XDR) carbapenemase-producing Klebsiella pneumoniae and other Enterobacterales, as well as Pseudomonas aeruginosa and pan-drug resistant (PDR) Acinetobacter baumannii. Recently, a more precise definition of resistance for Gram-negative bacilli, defined as difficult-to-treat resistance (DTR), has been proposed, indicating treatment-limiting resistance to all β-lactams and fluoroquinolones. The burden of global resistance in 2019 mounted to 4.95 million deaths, of which 1.27 million were directly attributable to bacterial antimicrobial resistance, whereas in the USA the CDC has estimated that 2.868.700 people were infected with antibiotic-resistant bacteria and fungi, resulting in 35.900 deaths each year. The constantly increasing global threat of antibiotic resistance, which has resulted in countless untreatable infections and deaths, demands the urgent need for a strategic action plan. The fact that humanity is approaching the “End of the Miracle Drugs”, due to their unjustifiable overuse and misuse, has prompted a vast concerted effort to combat resistance by implementing antibiotic stewardship programs within healthcare institutions, designed to guide rational antibiotic utilization. Furthermore, newer strategies to mitigate the existing resistance, and preventing resistance to newer compounds being developed, based on the appropriate handling of newer antibiotics, are urgently required.

Prof. Dr. Helen Giamarellou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotic stewardship
  • PDR
  • DTR
  • Gram-negative bacilli
  • newer β-lactamase inhibitors

Published Papers

This special issue is now open for submission.
Back to TopTop